Expression of the Non-classical HLA-E, -F, -G Molecules in the Tumour Microenvironment
References
- Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics. CA Cancer J Clin. 2022;72(1):7–33.
- Cancer 2020. Available from: https://www.who.int/news-room/fact-sheets/detail/cancer.
- da Silva GBRF, Silva TGA, Duarte RA, et al. Expression of the classical and nonclassical HLA molecules in breast cancer. Int J Breast Cancer. 2013;1–9.
- Seliger B, Kloor M, Ferrone S. HLA class II antigen-processing pathway in tumors: Molecular defects and clinical relevance. Oncoimmunology. 2017;6(2):1–10.
- Niranjana AN, Gonzalez F. Non-classical MHC class Ib-restricted cytotoxic T cells monitor antigen processing in the endoplasmic reticulum. Nat Immunol. 2012;13(6):579–586.
- Bukur J, Jasinski S, Seliger B. The role of classical and non-classical HLA class I antigens in human tumors. Semin Cancer Biol. 2012;22(4):350–358.
- Adams EJ, Luoma AM. The adaptable major histocompatibility complex (MHC) fold: Structure and function of nonclassical and mhc class I-like molecules. Annual Review of Immunology. 2013; 31:529–561.
- Robinson J, Barker DJ, Georgiou X, et al. IPD-IMGT/HLA Database. Nucleic Acids Res. 2020; 48(D1):948–955.
- Morandi F, Pistoia V. Interactions between HLA-G and HLA-E in physiological and pathological conditions. Front Immunol. 2014;5:1–6.
- Tronik-Le Roux D, Renard J, Vérine J, et al. Novel landscape of HLA-G isoforms expressed in clear cell renal cell carcinoma patients. Molecular Oncology. 2017;11:561–578.
- Zhang Y, Yu S, Han Y. Human leucocyte antigen-G expression and polymorphisms promote cancer development and guide cancer diagnosis/treatment. Oncol Lett. 2018;15:699–709.
- Campoli M, Ferrone S. HLA antigen and NK cell activating ligand expression in malignant cells: A story of loss or acquisition. Semin Immunopathol. 2011;33:321–334.
- Reimers MS, Engels CC, Putter H, et al. Prognostic value of HLA class I, HLA-E, HLA-G and Tregs in rectal cancer: A retrospective cohort study. BMC Cancer. 2014;14(1):1–12.
- Borst L, van der Burg SH, van Hall T. The NKG2A-HLA-E axis as a novel checkpoint in the tumor microenvironment. Clin Cancer Res. 2021;26(21):5549–5556.
- Kamiya T, Seow SV, Wong D. Blocking expression of inhibitory receptor NKG2A overcomes tumor resistance to NK cells. J Clin Invest. 2019;129(5):2094–2106.
- Wagner B, da Silva Nardi F, Schramm S, et al. HLA-E allelic genotype correlates with HLA-E plasma levels and predicts early progression in chronic lymphocytic leukemia. Cancer. 2017;123(5):814–823.
- Lin A, Yan WH. The emerging roles of human leukocyte antigen-F in immune modulation and viral infection. Front Immunol. 2019;10:1–7.
- Lin A, Zhang X, Ruan YY, et al. HLA-F expression is a prognostic factor in patients with non-small-cell lung cancer. Lung Cancer. 2011;74(3):504–509.
- Loustau M, Anna F, Dréan R, et al. HLA-G neo-expression on tumors. Front Immunol. 2020;11:1–15.
- Lin A, Yan WH. Human leukocyte antigen-G (HLA-G) expression in cancers: Roles in immune evasion, metastasis and target for therapy. Mol Med. 2015;21:782–791.
- Rouas-Freiss N, Moreau P, LeMaoult J, et al. The dual role of HLA-G in cancer. J Immunol Res. 2014;1–10.
- Liu L, Wang L, Zhao L, et al. The role of HLA-G in tumor escape: Manipulating the phenotype and function of immune cells. Front Oncol. 2020;10:1–11.
- Paul P, Rouas-Freiss N, Khalil-Daher I, et al. HLA-G expression in melanoma: A way for tumor cells to escape from immunosurveillance. Proc Natl Acad Sci USA. 1998;95(8):4510–4515.
- Derré L, Corvaisier M, Charreau B, et al. Expression and release of HLA-E by melanoma cells and melanocytes: Potential impact on the response of cytotoxic effector cells. J Immunol. 2006; 177(5):3100–3107.
- Allard M, Oger R, Vignard V, et al. Serum soluble HLA-E in melanoma: A new potential immune-related marker in cancer. PLoS One. 2011;6:6.
- Urosevic M, Dummer R. HLA-G in skin cancer: A wolf in sheep’s clothing? Hum Immunol. 2003; 64(11):1073–1080.
- Urosevic M, Kempf W, Zagrodnik B, et al. HLA-G expression in basal cell carcinomas of the skin recurring after radiotherapy. Clin Exp Dermatol. 2005;30(4):422–425.
- Zheng J, Xu C, Chu D, et al. Human leukocyte antigen G is associated with esophageal squamous cell carcinoma progression and poor prognosis. Immunol Lett. 2014;161(1):13–19.
- Yie SM, Yang H, Ye SR, et al. Expression of HLA-G is associated with prognosis in esophageal squamous cell carcinoma. Am J Clin Pathol. 2007;128(6):1002–1009.
- Julie B, Charles P, Wisnivesky J. Global epidemiology of lung cancer. Ann Glob Heal. 2019;1–16.
- Yazdi MT, van Riet S, van Schadewijk A, et al. The positive prognostic effect of stromal CD8+ tumor-infiltrating T cells is restrained by the expression of HLA-E in non-small cell lung carcinoma. Oncotarget. 2016;7(3):3477–3488.
- Llovet J, Kelley R, Villanueva A. Hepatocellular carcinoma. Nat Rev Dis Prim. 2021;7(6):1–28.
- Xu Y, Han H, Zhang F. Lesion human leukocyte antigen-F expression is associated with a poor prognosis in patients with hepatocellular carcinoma. Oncol Lett. 2015;9:300–304.
- Crew K, Neugut A. Epidemiology of gastric cancer. World J Gastroenterol. 2006;12(3):354–362.
- Murdaca G, Calamaro P, Lantieri F, et al. HLA-G expression in gastric carcinoma: Clinicopathological correlations and prognostic impact. Virchows Arch. 2018;473(4):425–433.
- Zeestraten ECM, Reimers MS, Saadatmand S, et al. Combined analysis of HLA class I, HLA-E and HLA-G predicts prognosis in colon cancer patients. Br J Cancer. 2014;110(2):459–468.
- Guo ZY, Lv YG, Wang L, et al. Predictive value of HLA-G and HLA-E in the prognosis of colorectal cancer patients. Cell Immunol. 2015;293(1):10–16.
- Ye S, Yang H, Li K. Human leukocyte antigen G expression: As a significant prognostic indicator for patients with colorectal cancer. Mod Pathol. 2007;20:375–383.
- Breastcancer.org. https://www.breastcancer.org/symptoms/understand_bc/statistics.
- Menier C, Rouas-Freiss N, Favier B, et al. Recent advances on the non-classical major histocompatibility complex class i HLA-G molecule. Tissue Antigens. 2010;75(3):201–206.
- de Kruijf EM, Sajet A, van Nes JGH, et al. HLA-E and HLA-G expression in classical HLA class I-negative tumors is of prognostic value for clinical outcome of early breast cancer patients. J Immunol. 2010;185(12):7452–7459.
- Harada A, Ishigami S, Kijima Y, et al. Clinical implication of human leukocyte antigen (HLA)-F expression in breast cancer. Pathol Int. 2015;65(11):569–574.
- Gooden M, Lampen M, Jordanova ES, et al. HLA-E expression by gynecological cancers restrains tumor-infiltrating CD8 + T lymphocytes. Proc Natl Acad Sci USA. 2011;108(26):10656–10661.
- Van Esch EMG, Tummers B, Baartmans V, et al. Alterations in classical and nonclassical HLA expression in recurrent and progressive HPV-induced usual vulvar intraepithelial neoplasia and implications for immunotherapy. Int J Cancer. 2014;135(4):830–842.
- Centers for Disease Control and Prevention. Ovarian cancer statistics. https://www.cdc.gov/cancer/ovarian/statistics/.
- Babay W, Ben Yahia H, Boujelbene N, et al. Clinicopathologic significance of HLA-G and HLA-E molecules in Tunisian patients with ovarian carcinoma. Hum Immunol. 2018;79(6):463–470.
- Kanevskiy L, Erokhina S, Kobyzeva P, et al. Dimorphism of HLA-E and its disease association. Int J Mol Sci. 2019;20(21):1–16.
- Guan J, Xie L, Luo X. The prognostic significance of estrogen and progesterone receptors in grade I and II endometrioid endometrial adenocarcinoma: Hormone receptors in risk stratification. Gynecol Oncol. 2019;30(1):1–14.
- Bijen CBM, Bantema-Joppe EJ, De Jong RA, et al. The prognostic role of classical and nonclassical MHC class I expression in endometrial cancer. Int J Cancer. 2010;126(6):1417–1427.
- Haque A, Banik NL, Ray SK. Molecular alterations in glioblastoma: Potential targets for immunotherapy. Prog Mol Bio and Trans Sci. 2011;98:187–234
- Wu Z, Liang J, Wang Z, et al. HLA-E expression in diffuse glioma: Relationship with clinicopathological features and patient survival. BMC Neurol. 2020;20(1):1–7.
- Bukova M, Kluckova K, Kozak J. HLA-G 14 bp ins/del polymorphism, plasma level of soluble HLA-G and association with IL-6/IL-10 ratio and survival of glioma patients. Prepr. 2021;1–23.
- Wagner B, Nardi F, Schramm S. HLA-E allelic genotype correlates with HLA-E plasma levels and predicts early progression in chronic lymphocytic leukemia. Wiley Online Libr. 2016;814–823.
- Nückel H, Rebmann V, Dürig J, et al. HLA-G expression is associated with an unfavorable outcome and immunodeficiency in chronic lymphocytic leukemia. Blood. 2005;105(4):1694–1698.
- Yan WH, Lin A, Chen BG, et al. Unfavourable clinical implications for HLA-G expression in acute myeloid leukaemia. J Cell Mol Med. 2008;12(3):889–898.
- Sebti Y, Le Maux A, Gros F, et al. Expression of functional soluble human leucocyte antigen-G molecules in lymphoproliferative disorders. Br J Haematol. 2007;138(2):202–212.
- Jesionek-Kupnicka D, Bojo M, Prochorec-Sobieszek M. HLA-G and MHC class II protein expression in diffuse large B-cell lymphoma. Blood. 2016;64(3):225–240.
- Diepstra A, Poppema S, Boot M, et al. HLA-G protein expression as a potential immune escape mechanism in classical Hodgkin’s lymphoma. Tissue Antigens. 2008;71(3):219–226.
- Caocci G, Greco M, Fanni D, et al. HLA-G expression and role in advanced-stage classical Hodgkin lymphoma. Eur J Histochem. 2016;60(2):1–6.
- Martin P, Krsnik I, Navarro B. HLA allele E*01:01 is associated with a reduced risk of EBV-related classical Hodgkin lymphoma independently of HLA-A*01/*02. PLoS One. 2015;1–13.
- Amiot L, Ferrone S, Grosse-Wilde H, et al. Biology of HLA-G in cancer: A candidate molecule for therapeutic intervention? Cell Mol Life Sci. 2011;68(3):417–431.
- Adolf IC, Almars A, Dharsee N, et al. HLA-G and single nucleotide polymorphism (SNP) associations with cancer in African populations: Implications in personal medicine. Genes Dis. 2021;9(5):1220–1233.
- Belén Palma M, Tronik-Le Roux D, Amín G, et al. HLA-G gene editing: A novel therapeutic alternative in cancer immunotherapy. bioRxiv. 2021. <a href="https://doi.org/10.1101/2021.01.21.427294." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1101/2021.01.21.427294.</a>
Language: English
Page range: 53 - 62
Submitted on: Sep 20, 2022
Accepted on: Jan 9, 2023
Published on: Aug 3, 2023
Published by: Helenic Society of Medical Oncology
In partnership with: Paradigm Publishing Services
Publication frequency: 2 times per year
Keywords:
Related subjects:
© 2023 Anastasia Ormandjieva, published by Helenic Society of Medical Oncology
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.